Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

Barbara Jezer&scaron;ek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezer&scaron;ek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zalo&scaron;ka 2,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jezeršek Novaković B, Boltežar L, Novaković A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	pixantrone b-cell non-hodgkin lymphomas efficacy toxicity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/a7a07d97bfa349708902b90ce5f124bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a7a07d97bfa349708902b90ce5f124bc
record_format	dspace
spelling	oai:doaj.org-article:a7a07d97bfa349708902b90ce5f124bc2021-12-02T14:35:26ZCurrent Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma1178-203Xhttps://doaj.org/article/a7a07d97bfa349708902b90ce5f124bc2021-03-01T00:00:00Zhttps://www.dovepress.com/current-opinion-on-pixantrone-in-the-treatment-of-non-hodgkin-b-cell-l-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XBarbara Jezer&scaron;ek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezer&scaron;ek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zalo&scaron;ka 2, Ljubljana, 1000, SloveniaTel +38615879631Fax +38615879305Email bjezersek@onko-i.siAbstract: Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas.Keywords: pixantrone, B-cell non-Hodgkin lymphomas, efficacy, toxicityJezeršek Novaković BBoltežar LNovaković ADove Medical Pressarticlepixantroneb-cell non-hodgkin lymphomasefficacytoxicityTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 183-192 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pixantrone b-cell non-hodgkin lymphomas efficacy toxicity Therapeutics. Pharmacology RM1-950
spellingShingle	pixantrone b-cell non-hodgkin lymphomas efficacy toxicity Therapeutics. Pharmacology RM1-950 Jezeršek Novaković B Boltežar L Novaković A Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
description	Barbara Jezer&scaron;ek Novaković, Lučka Boltežar, Aleksander NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, SloveniaCorrespondence: Barbara Jezer&scaron;ek NovakovićDivision of Medical Oncology, Institute of Oncology Ljubljana, Zalo&scaron;ka 2, Ljubljana, 1000, SloveniaTel +38615879631Fax +38615879305Email bjezersek@onko-i.siAbstract: Not many treatment options exist for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in whom first- and second-line therapies were unsuccessful. This is especially true for patients with aggressive lymphomas. The innovative agent pixantrone has shown some promising results in terms of disease-free and overall survival, both in monotherapy as well as in combinations. However, recent trials (Phase III and real-world studies) reported unsatisfactory results, thereby raising the question about the role of pixantrone in the current treatment of R/R aggressive lymphomas. Nonetheless, there might still be a potential position for this drug in combinations, for use as first-line treatment of patients with cardiac dysfunction. This article summarizes the definition, structure, mechanism of action and reduced cardiotoxicity of pixantrone as well as efficacy and toxicity both in monotherapy and in combinations, as treatment for aggressive and indolent non-Hodgkin lymphomas.Keywords: pixantrone, B-cell non-Hodgkin lymphomas, efficacy, toxicity
format	article
author	Jezeršek Novaković B Boltežar L Novaković A
author_facet	Jezeršek Novaković B Boltežar L Novaković A
author_sort	Jezeršek Novaković B
title	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
title_short	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
title_full	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
title_fullStr	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
title_full_unstemmed	Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma
title_sort	current opinion on pixantrone in the treatment of non-hodgkin b-cell lymphoma
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/a7a07d97bfa349708902b90ce5f124bc
work_keys_str_mv	AT jezerseknovakovicb currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma AT boltezarl currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma AT novakovica currentopiniononpixantroneinthetreatmentofnonhodgkinbcelllymphoma
_version_	1718391149695074304

Current Opinion on Pixantrone in the Treatment of Non-Hodgkin B-Cell Lymphoma

Ejemplares similares